CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 100 enrolled
Drug / intervention
Quadrivalent Influenza Vaccine (split virion, inactivated)biological
Likely dose
Quadrivalent Influenza Vaccine (split virion, inactivated) 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01967784
NCT01967784Phase 3Completed
CompareCT.gov

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan

Sanofi Pasteur, a Sanofi Company·interventional·Posted Oct 23, 2013·Updated Jan 20, 2016

In Brief

A Phase 3 clinical trial evaluating Quadrivalent Influenza Vaccine (split virion, inactivated) for Influenza. Completed, enrolled 100 participants across 2 sites.

Detailed Summary

The aim of the study is to describe the immunogenicity and safety of the new formulation of Quadrivalent Influenza Vaccine (QIV) for the 2013-2014 season in the Northern Hemisphere (NH) in subjects aged 9 to 17 years in Taiwan Primary Objective: * To describe the immunogenicity of the QIV (split-virion, inactivated) NH seasonal formulation Secondary Objective: * To describe the safety of the QIV (split-virion, inactivated) NH seasonal formulation

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesTaiwan
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 23, 2013
Enrollment StartOct 1, 2013
Primary CompletionApr 1, 2014
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.7 years ago

Interventions

Quadrivalent Influenza Vaccine (split virion, inactivated)biological

0.5 mL, Intramuscular